Drug Trial Radar · NCT00683111
Prevention of Gastrointestinal Bleeding in Patients With Severe Ischemic Heart Disease
Last checked: Nov 19, 2026Latest source record: Jun 6, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
500
Planned (sponsor's estimate)
Start
Jul 2008
Primary completion
Dec 2011
Study completion Dec 2011
Sponsor
- Lead sponsor
- Ruttonjee HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 23, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Aspirin and clopidogrel +/- heparin or thrombolytic co-therapy is well established and effective treatment for unstable cardiac patients. However, the major complication was gastrointestinal bleeding (GIB) due to peptic ulcer. In the prevention of GIB, anti-ulcer drug either H2-receptor antagonist (H2RA) and proton pump inhibitor (PPI) were commonly prescribed. There has been no prospective controlled study to compare the efficacy of these two classes of anti-ulcer drugs.
Conditions
- Acute Coronary Syndrome
- Acute Myocardial Infarction
Interventions
esomeprazole 20 mg dailyDrug
oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for up to 12 months
famotidine 40 mg dailyDrug
oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for up to 12 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- ulcer complication (bleeding/perforation/obstruction)Time frame: up to 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ruttonjee Hospital
Hong Kong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.